• Masitinib (AB1010): Technical Use in KIT/PDGFR Research

  2026-06-18

  Masitinib (AB1010) is a selective phenylaminothiazole-type tyrosine kinase inhibitor designed for precise inhibition of KIT, PDGFRα, and PDGFRβ in cancer biology, mastocytosis, and inflammatory disease models. Researchers should use it only in DMSO-based workflows and avoid aqueous or ethanol-based systems, as well as protocols requiring broad-spectrum kinase inhibition.

• Entinostat (MS-275): Precision Tools for Cancer Cell Fate An

  2026-06-18

  Explore Entinostat (MS-275), a selective HDAC inhibitor, as a precision tool for dissecting cancer cell proliferation and apoptosis. This in-depth article uniquely bridges advanced in vitro assay design with translational oncology, delivering actionable insights for researchers.

• U 46619: Precision Platelet Aggregation Inducer for Vascular

  2026-06-17

  U 46619 (11,9 epoxymethano-prostaglandin H2) empowers researchers to reproducibly dissect TP receptor signaling and platelet function, offering robust protocol control in cardiovascular and renal studies. This article details practical workflows, troubleshooting insights, and direct translation of reference evidence into assay design, positioning APExBIO’s U 46619 as a gold-standard tool for mechanistic and translational research.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-06-17

  This study reveals that certain kinase inhibitors not only block kinase activity but also promote dephosphorylation of p38α MAP kinase by stabilizing a specific inactive conformation. Structural and mechanistic insights suggest a new strategy to enhance specificity and potency in kinase-targeted research and therapeutic development.

• Estradiol Benzoate: High-Affinity Estrogen Receptor Alpha Ag

  2026-06-16

  Estradiol Benzoate is a synthetic estradiol analog and potent estrogen receptor alpha agonist. It exhibits an IC50 of 22–28 nM for ERα binding and is widely used in estrogen receptor signaling research. Supplied by APExBIO, it delivers high purity and robust solubility for reliable hormone receptor assays.

• Sunitinib Resistance in RCC: Mechanistic Insights and Future

  2026-06-16

  This thought-leadership article explores the evolving landscape of sunitinib resistance in renal cell carcinoma (RCC), blending a mechanistic understanding of multi-targeted receptor tyrosine kinase (RTK) inhibition with actionable guidance for translational researchers. By integrating recent discoveries on ferroptosis, combination strategies, and robust experimental protocols, it offers a forward-looking roadmap for overcoming therapeutic barriers and maximizing research impact.

• HotStart™ 2X Green qPCR Master Mix: Precision for Biomarker

  2026-06-15

  Discover how HotStart 2X Green qPCR Master Mix advances SYBR Green qPCR for biomarker validation in oncology. Explore protocol depth, assay optimization, and novel insights for translational biomarker research.

• Protocols for Avian Auditory Hair Cell Ablation and Regenera

  2026-06-15

  This reference paper establishes a reproducible protocol for targeted elimination of avian auditory hair cells, followed by multiplexed mRNA detection, immunohistochemistry, and S-phase labeling to analyze regeneration. The methodology enables high-resolution dissection of gene expression and proliferative responses in the regenerating inner ear, advancing mechanistic studies of sensory recovery.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-06-14

  The reference study reveals that certain kinase inhibitors, including those relevant to Imatinib hydrochloride (STI571 hydrochloride), not only inhibit kinase activity but also enhance dephosphorylation of p38α MAP kinase by stabilizing a conformation favorable for phosphatase activity. This dual-action mechanism deepens our understanding of kinase-phosphatase dynamics and suggests new strategies for developing more selective and potent kinase inhibitors in cancer research.

• O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Format

  2026-06-13

  This study uncovers how O-GlcNAcylation serves as a key mediator of Wnt3a-induced bone formation by rewiring aerobic glycolysis in osteoblasts. The findings reveal a dual mechanism for O-GlcNAcylation activation and identify its indispensability for osteogenesis, offering new insights for metabolic and signaling pathway research in bone biology.

• Nebivolol Hydrochloride: Selectivity, Assay Design, and mTOR

  2026-06-12

  Explore Nebivolol hydrochloride as a highly selective β1-adrenoceptor antagonist for cardiovascular and signaling research. This article reveals new experimental considerations, recent mTOR pathway findings, and advanced assay design strategies beyond typical applications.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Inhibition Wo

  2026-06-12

  Masitinib (AB1010) addresses the need for precise inhibition of the KIT, PDGFRα, and PDGFRβ tyrosine kinases in cancer biology, mastocytosis, and inflammation model systems. It is best suited for DMSO-based workflows where selective kinase targeting is required and should not be used in protocols that depend on broad-spectrum inhibition or require aqueous/ethanol solubility.

• Imatinib Hydrochloride: Optimized Workflows for Kinase Inhib

  2026-06-11

  Imatinib hydrochloride enables precise, multi-target kinase inhibition for advanced cancer research, from CML to GISTs. This article details experimental best practices, protocol optimization, and troubleshooting tips, leveraging both emerging mechanistic insights and APExBIO’s high-purity reagent standards.

• Epigenetic Modulation Shapes Immune Signatures in Melanoma

  2026-06-11

  Anichini et al. (2022) systematically profiled immune-related gene signatures induced by different classes of epigenetic regulators in melanoma, finding that the DNMT inhibitor guadecitabine uniquely enhances immune activation programs with clinical relevance. Their findings clarify the molecular rationale for combining specific epigenetic drugs with immunotherapy, offering new directions for translational cancer research.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Eviden

  2026-06-10

  A recent open-access study demonstrates that intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) can restore tumor suppressor function and suppress tumor growth in non–muscle-invasive bladder cancer. This approach leverages localized mRNA therapy to overcome limitations of standard treatments, with strong mechanistic and preclinical support for clinical translation.

15206 records 1/1014 page Next 12345 下5页 Last page